In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


McClellan, Wall Street and Increasing FDA Predictability

Executive Summary

The most encouraging aspect of the series of speeches the FDA's new commissioner, Mark McClellan, MD, PhD, has been giving is not what he says--we've heard most of this before--but to whom he says it: pharmaceutical investors and companies.

Related Content

FDA to Run Pilots Designed to Reduce Total NDA Review Time
Shaking Up the FDA
Pharmacogenomic Data and Labeling: A Less-Safe Harbor for Existing Drugs?
The Infrastructure Dilemma
An FDA Nominee, Biologics Reviews Move to CDER
PDUFA Extension Adds More than Funding
Why Don't Big Pharmas Buy Pharmacogenomics?
Why Don't Big Pharmas Buy Pharmacogenomics?
A Gun-Shy FDA?
The Efficacy Challenge





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts